An advisory panel to the FDA voted nine to six against the agency approving dapagliflozin, a diabetes treatment developed by New York-based Bristol-Myers Squibb (NYSE: [[ticker:BMY]]) and AstraZeneca (NYSE: [[ticker:AZN]]), according to a press release. Dapagliflozin is among a new class of drugs designed to inhibit SGLT2, a protein that promotes the reabsorption of glucose by the body. The FDA doesn’t have to follow the recommendations of its advisory panels, but it usually does. The panel’s rejection led Goldman Sachs analyst Jami Rubin to declare in a report “SGLT2 class likely dead.”
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
View all posts by Arlene Weintraub
